The 5 most recent market catalysts affecting $USPH, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 18, 2026
Corporate Catalyst
Neutral
Impact 90
Transcript: US Physical Therapy Q2 2026 Earnings Conference Call
US Physical Therapy (USPH) reported robust Q2 2026 results, including an 8.5% revenue increase and record visits per clinic per day, reaching an all-time high of 33.5. A key highli…
Sep 11, 2026
Corporate Catalyst
Bullish
Impact 55
JP Morgan Maintains Overweight on US Physical Therapy, Raises Price Target to $95
JP Morgan analyst Benjamin Rossi has raised the price target for US Physical Therapy (USPH) from $90 to $95, while maintaining an Overweight rating. This action signals continued c…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 55
U.S. Physical Therapy Announces Appointment Of Nchacha Etta As CFO Effective September 1, Succeeding Interim CFO Jason Curtis
The appointment of Nchacha Etta as CFO for U.S. Physical Therapy is a corporate catalyst, primarily impacting the company itself. While the immediate market reaction is likely neut…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Barrington Research Maintains Outperform on US Physical Therapy, Raises Price Target to $98
Barrington Research's decision to raise the price target for US Physical Therapy (USPH) from $90 to $98, while maintaining an Outperform rating, signals increased confidence in the…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 92
US Physical Therapy Q2 Adj. EPS $0.75 Misses $0.84 Estimate, Sales $214.059M Beat $211.307M Estimate
US Physical Therapy (USPH) reported a significant miss on its Q2 adjusted EPS, coming in at $0.75 against an $0.84 estimate, a 10.71% deviation. This earnings miss, coupled with a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.